Latuda: An Evaluation of Its Usefulness

With nine other atypical antipsychotics already on the market (some of which are available as generics), did we really need another one? Given the pesky side effects of antipsychotics, maybe we did. Let’s take a look at what we know so far about Latuda (lurasidone) in an effort to figure out how to incorporate it into our clinical toolbox. Latuda was first approved by the US Food and Drug Administration (FDA) for use in schizophrenia in late 2010.

Glutamate’s Role in Schizophrenia

Schizophrenia - The Carlat Psychiatry Report (TCPR)

There’s a rich history of research suggesting that glutamate may be involved in the pathogenesis of schizophrenia, with an increasing amount of attention being brought to glutamate during the past decade or so.

Atypical Antipsychotics: Where is the Science, Where is the Evidence?

Any psychiatrist who has practiced during the last decade has probably written more than a few prescriptions for an atypical antipsychotic. But do these drugs provide any clear advantages over their predecessors?

Research Update

Some Popular Antipsychotics May Not be Effective in Patients over 40

Atypical antipsychotics are widely prescribed for a number of psychiatric diagnoses, but their real-world effectiveness has rarely been evaluated in anything other than short-term trials. A recently published study finds that four commonly used antipsychotics (aripiprazole [Abilify], olanzapine [Zyprexa], quetiapine [Seroquel], and risperidone [Risperdal]), when used in patients over age 40 with schizophrenia or psychosis associated with other conditions, may not be effective—and cause frequent side effects.

Off-Label Use of Antipsychotics Effective for Some Indications

Over the past decade or so, atypical antipsychotic use has exploded, for both FDA approved indications and off-label treatments. A recent meta-analysis examined the efficacy (when compared to placebo), comparative effectiveness (when compared to another medication), and safety of atypicals.

Expert QA

Attenuated Psychosis Syndrome

Dr. Carpenter, you are a member of the DSM-5 work group that is considering risk syndrome for first psychosis, or what is now called “attenuated psychosis syndrome” as a new diagnosis in the manual.

Free Article

The Psychosis Prodrome [Free Article]

The Carlat Psychiatry Report - TCPR - January 2013

At the crossroads of these experiences lies the concept of the psychosis prodrome and early intervention/prevention efforts. But without evidence of a florid psychotic episode, when should one intervene?

Latuda: “Procognitive” or Pro-Profit? [Free Article]


Lurasidone (Latuda) was approved by the FDA for schizophrenia in October 2010 and is the 10th atypical antipsychotic in our toolbox. The key question is: does lurasidone have any advantages over existing agents, or is it just another “me-too” drug?